AIM2 and systemic lupus erythematosus: Recent studies have shown that the expression of AIM2 gene can be a biomarker to predict the benefit of therapy in patients with epithelial ovarian cancer (Hsu et al., 2021), melanoma (Fukuda et al., 2021), systemic lupus erythematosus (Yang et al., 2021) and heart failure (Onódi et al., 2021).